News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Somnus Therapeutics Inc. Developing Medication to Prevent Middle-of-the-Night Awakening with No Adverse Effects on Next Day Performance



6/9/2010 10:48:44 AM

SAN ANTONIO--(BUSINESS WIRE)--Many insomnia sufferers fall asleep readily but have trouble sleeping through the night. Middle-of-the-night (MOTN) awakening is an issue not well-addressed by currently available sleep medications, particularly agents that not only induce sleep immediately, but that can also leave users with unwanted next-day effects, such as sleepiness, as well as impaired motor function, memory and reaction time. Clinical research on SKP-1041, a delayed-release formulation of zaleplon, under development by Somnus Therapeutics, Inc., suggests that SKP-1041 may enable natural sleep induction and prevent MOTN awakening with no residual cognitive or motor effects.

Read at BioSpace.com


comments powered by Disqus
   
Insomnia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES